Professional
Added to YB: 2024-10-23
Pitch date: 2024-09-30
207940.KS [bullish]
Samsung Biologics Co.,Ltd.
+37.08%
current return
Author Info
No bio for this author
Company Info
Samsung Biologics Co.,Ltd. engages in the contract development and manufacturing organization (CDMO) business for biopharmaceuticals products in South Korea, Europe, the United States, and internationally.
Market Cap
KRW 74.5T
Pitch Price
KRW 1.2M
Price Target
N/A
Dividend
N/A
EV/EBITDA
39.36
P/E
72.46
EV/Sales
17.72
Sector
Life Sciences Tools and Services
Category
growth
Baron Emerging Markets Fund New Position: Samsung Biologics Co.,Ltd.
207940.KS: Samsung Biologics, 3rd largest CDMO globally, benefits from outsourcing trend. World's largest capacity post-Plant 4 ramp-up. Plant 5 expansion in 2025. US Biosecure Act may restrict Chinese CDMOs, boosting Samsung. Competitive pricing vs Lonza. Central bank easing to accelerate biopharma activity.
Read full article (2 min)